Related Experiment Video
Updated: Feb 3, 2026

Prostaglandin Extraction and Analysis in Caenorhabditis elegans
Published on: June 25, 2013
A Child with Prostaglandin I2-associated Thyrotoxicosis: Case Report
Yuri Sonoda1, Kenichiro Yamamura1, Kanako Ishii1
1Kyushu University Graduate School of Medical Sciences, Department of Pediatrics, Fukuoka, Japan
Insights
Prostaglandin I2 (PGI2) therapy for pulmonary arterial hypertension (PAH) can cause hyperthyroidism in children with congenital portosystemic venous shunt syndrome (CPSVS). Prophylactic thyroid monitoring is recommended during PGI2 treatment.
Area of Science:
- Pediatric Endocrinology
- Cardiology
- Hepatology
Background:
- Pulmonary arterial hypertension (PAH) is a serious complication in children with congenital portosystemic venous shunt syndrome (CPSVS).
- Prostaglandin I2 (PGI2) therapy is used for PAH, but its effects on thyroid function in CPSVS patients are not well understood.
- Hyperthyroidism is a known complication of PGI2 in adult PAH patients.
Observation:
- A pediatric case of CPSVS with PAH developed thyrotoxicosis during PGI2 treatment.
- Literature review identified 12 additional pediatric PAH patients treated with PGI2 who developed hyperthyroidism.
- Hyperthyroidism during PGI2 treatment was associated with a high mortality rate in pediatric PAH patients.
Findings:
- PGI2 therapy is linked to hyperthyroidism in children with CPSVS and PAH.
- The onset of hyperthyroidism can occur years after initiating PGI2 treatment.
- Hyperthyroidism poses a significant risk, potentially leading to fatal PAH crises.
Implications:
- Prophylactic thyroid function monitoring is crucial for children with CPSVS receiving PGI2 therapy.
- Early detection and management of hyperthyroidism may improve outcomes in this vulnerable population.
- This study highlights the need for careful risk-benefit assessment of PGI2 in pediatric CPSVS patients.
Abstract:
Prostaglandin I2 (PGI2) causes hyperthyroidism, a critical complication in patients with pulmonary arterial hypertension (PAH). However, it remains unknown whether PGI2 may have unfavorable effects on thyroid function in children with congenital portosystemic venous shunt syndrome (CPSVS). We present a boy with CPSVS who developed PAH at seven years of age. During ongoing PGI2 therapy, he experienced thyrotoxicosis at 17 years of age. The literature review showed that the reported 12 patients with PAH (median 11 years of age) developed hyperthyroidism during between one and 11 years of PGI2 treatment. Only one patient survived the acute PAH crisis due to hyperthyroidism. These data provide evidence that prophylactic intervention for hyperthyroidism is indicated for children with CPSVS during PGI2 treatment.
More Related Videos
Related Concept Videos
Data Reporting and Recording
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:
Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
Types of Reports III: Telephone and Verbal Reports
Here's an overview of each type:
Telephone Orders
Reporter Genes
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

